Breast cancer is one of the leading causes of cancer death worldwide. Approximately 70% of breast cancers express the estrogen receptor. Inhibition of this receptor can shrink and control breast cancers. One of the oldest drugs is tamoxifen, a selective estrogen receptor modulator which inhibitors the estrogen receptor in the breast, but stimulates the estrogen receptor in the bone and uterus.
There is a clear benefit with the use of tamoxifen in patients with stage III and IV cancers. In an effort to supply more tamoxifen to developing countries, we aim to purchase this drug in bulk and to deliver it to public cancer hospitals with the lowest possible margin to be able to help the largest number of people.